[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
January 19, 2011

Mapping Out Biomarkers for Alzheimer Disease

Author Affiliations

Author Affiliations: Department of Epidemiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands; and DZNE, German Center for Neurodegenerative Diseases, Bonn, Germany.

JAMA. 2011;305(3):304-305. doi:10.1001/jama.2010.2017

The last decade has seen a surge in research in biomarkers for Alzheimer disease (AD) and other dementia disorders. With predictions of 1 in 4 persons ultimately developing the disease, disorders causing dementia have become one of the major health concerns in aging societies. Impending costs to society and individuals, as well as the enormous and increasing market potential to industry, make this an extremely important field in which the stakes, pressure, and expectations are high to develop better means to establish presence of disease, monitor progression, and make a diagnosis. In that arena, it is of the utmost importance that biomarkers are evaluated in a valid and rigorous way.